Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=23731900
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
What are the immunological consequences of long-term use of biological therapies
for juvenile idiopathic arthritis?
#MMPMID23731900
Swart JF
; de Roock S
; Wulffraat NM
Arthritis Res Ther
2013[]; 15
(3
): 213
PMID23731900
show ga
This review summarizes the immunological consequences of biological therapies
used in juvenile idiopathic arthritis (JIA). For every frequently used biological
agent the characteristics are clearly specified (molecular target, isotype,
registered indication for JIA, route of administration, half-life,
contraindication, very common side effects, expected time of response and average
cost in the first year). The emphasis of this review is on the immunological side
effects that have been encountered for every separate agent in JIA populations.
For each agent these adverse events have been calculated as incidence per 100
patient-years for the following categories: serious infections, tuberculosis,
malignancies, response to vaccination, new-onset autoimmune diseases and
development of anti-drug antibodies. There are large differences in side effects
between various agents and there is a clear need for an international and
standardized collection of post-marketing surveillance data of biologicals in the
vulnerable group of JIA patients. Such an international pharmacovigilance
database, called Pharmachild, has now been started.
free
free
free
